Resources
- BNET Author Biography
- David P. Hamilton, a 14-year veteran of the Wall Street Journal, is a freelancebusiness and medical writer in San Francisco. He most recently founded theLifeScience section of VentureBeat, a news site for innovation and venturebusiness. Previously, David covered biotechnology, the Internet, and computingand served as a Tokyo foreign correspondent...
- more about David P. Hamilton »
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Pfizer Leads in Layoffs While Drug Prices Soar
- Big Pharma continues to lend new meaning to the phrase "doing more with less," because while the industry seems to get smaller every day, drugmakers are still pushing through big price increases on their leading products. Over at Pharmalot, Ed Silverman provides a helpful roundup tracking the...
- Blog posts 2008-04-10
- Glaxo Gets an FDA Warning... With Teeth
- Well before Vytorin became a cause célèbre -- which is to say, about a year ago -- GlaxoSmithKline was the drugmaker getting slapped around by critics for downplaying or ignoring possible heart problems associated with its diabetes drug Avandia. That case, which led to new warnings on the drug's label...
- Blog posts 2008-04-12
- Japanese Pharma Waves Its Charge Card
- Japanese drugmakers are anxious to expand their presence in global pharma/biotech markets where they've long been largely shut out -- and the strong yen is making it cheaper for them to basically buy their way in. Interestingly enough, some of these deals are bypassing the U.S. altogether. ...
- Blog posts 2008-06-12
- A Scientist's Take on Glaxo's Restructuring
- Chances are good that if you're a drug-industry scientist, you already know Derek Lowe's blog In the Pipeline, which often as not focuses on the complexities of chemical synthesis and research management. Even though he works at a lab bench, Lowe also has an excellent sense of what makes pharmaceutical...
- Blog posts 2008-06-16
- Is There Really a "Market Price" for Drugs?
- Everyone seems to be ganging up on high drug prices these days. In two separate hearings last week, Congressional committees took after drugmakers for big markups on specialty treatments and a pharma "windfall" created by the Medicare prescription-drug benefit, while the WSJ took a hard look at the opacity of...
- Blog posts 2008-07-27
- 23andMe's Price Cut: The End of Commerical Personal Genomics?
- A huge price cut by personal-genomics pioneer 23andMe may well herald the demise of the commercial personal-genomics business before it even really got started -- and for much the same reason that startups such as Celera Genomics saw their genome-based information businesses crash and burn almost a decade ago. by...
- Blog posts 2008-09-09
- New Media Opportunity for Drug Firms: Video Games
- Perhaps you're tired of seeing the same healthy-looking people in drug ads hiking across craggy rocks or picking up their grandkids or wafting gently off to sleep while a slew of side effects (in fine print, natch) scrolls quickly by. If so, the pharmaceutical industry has another offer for you:...
- Blog posts 2008-09-25
Additional Resources
- FDA Loosens Rules for Overseas Drug Trials
- Merrill Goozner, a former Chicago Tribune reporter turned public-health advocate he heads up the Integrity in Science Project at the Center for Science in the Public Interest, notes an interesting and almost wholly overlooked Food and Drug Administration decision that may have the effect of subjecting clinical-trial volunteers in poor...
- Blog posts 2008-05-08
- Man Bites Dog: Former Merck CEO Blasts High Drug Prices
- Most pharmaceutical companies insist that high drug prices are a natural consequence of the risky business of drug discovery, and that huge profits on marketed drugs are necessary to cover the costs of the 5,000 to 10,000 experimental drugs that fail for every one that succeeds. In fact, there are...
- Blog posts 2008-05-05
- Healthcare Roundup: Cardinal Health Spinoff, Hospitals Ditch Debt, and More
- Cardinal Health to spin off clinical, medical-product units -- The healthcare-services company said it will form a new $4 billion spinoff firm from units that handle distribution of surgical and medical products. Cardinal will retain drug and medical-supply chain services under its own roof. [Source: Health Data Management] ...
- Blog posts 2008-09-29
- FDA Slaps Down Genentech On Eye Drug
- The saga of Avastin and Lucentis -- two Genentech drugs used to treat a blinding condition called age-related macular degeneration, even though one is about 50 times cheaper than the other -- is one of those stories that just gets better the longer it goes on. A...
- Blog posts 2008-06-17
- More on 23andMe and the Future of Personal Genomics
- I've been remiss in addressing a particularly thoughtful response to my earlier post on 23andMe's price-cutting and its potential consequences for the future of personal genomics. So let me remedy that. To recap briefly: 23andMe, the spit-to-read-your-genome company, dropped its subscription price to $399 from $999, a...
- Blog posts 2008-09-30
- Healthcare Roundup: Wal-Mart Offers Employee PHRs, Health Plan Collapses, and More
- Wal-Mart offers employees personal-health records -- The retail giant said it would offer its employees electronic PHRs based on technology from WebMD and Dossia, an employer coalition. The company will pre-fill those records with prescription-drug and medical-treatment information from pharmacies and health-insurance companies. Of course, there's a catch: The plan...
- Blog posts 2008-10-01
- Rating and Ranking "Stealth Pharmas"
- A "stealth pharma," according to the folks at Pharmaceutical Executive, is any drug company that's not a Big Pharma. In other words, it's grab-bag of outfits that includes everything from specialty pharmas hawking retread drugs to biotechs to generics makers. Which, of course, makes them difficult to...
- Blog posts 2008-06-26
- Healthcare Roundup: No HLTH-WebMD Merger, Higher Medicaid Spending, Mental-Health Parity, and More
- HLTH, WebMD call off merger -- HLTH, a holding company that currently owns 84 percent of the publicly traded WebMD, pulled the plug on a proposed merger with that subsidiary. The companies cited financial-market uncertainty and difficulty finding a buyer for a second HLTH unit, Porex, which makes plastic products...
- Blog posts 2008-10-20
- Healthcare Roundup: Aetna-Microsoft Tie-Up, HCS Buys TMG Health, Navigenics Does Sequencing, and More
- Aetna ties up with Microsoft online-health records -- The big health-insurance firm Aetna said it will start allowing many of its members to transfer medical records kept by the insurer to Microsoft's HealthVault, a portable online health-record system. The information in question includes claims, diagnoses, test results and prescriptions. [Source:...
- Blog posts 2008-10-22
- Glaxo Makes Like Ponce de Leon With Sirtris Buy
- You can't fault GlaxoSmithKline for temerity. The U.K. drugmaker's unexpectedly large $720 million bid for Sirtris Pharmaceuticals represents a gutsy bet that the Massachusetts biotech really has a handle on a class of drugs that slow aging. Not that anyone at either company is eager to describe their work that...
- Blog posts 2008-04-22
- FDA to Biotech: Don't Blame Us For Your Cruddy Data
- For the past few years, a coterie of biotech executives, desperate patients and ideologues have waged a low-level but steady campaign to convince the country that the Food and Drug Administration is condemning sick Americans to death by denying them potentially life-saving cancer drugs and other treatments. For all three,...
- Blog posts 2008-05-29
- Esperion Escapes the Pfizer Borg
- Esperion Therapeutics, a biotech that Pfizer spent $1.3 billion acquiring in 2003, is free once more. And its founder, Roger Newton, is apparently putting the band back together. Newton, in fact, has just pulled off one of the rarer and most complicated moves in biotechnology -- the...
- Blog posts 2008-05-01
- Life Without Blockbusters: What Valeant's Woes Portend for Pharma
- It's now a truism that the drug industry's "blockbuster model" has pretty much had its day. Much of Big Pharma is having a terrible time winning approval for new drugs and even keeping up sales of existing blockbusters, in part because their underlying rationale -- that pushing drugs into mass...
- Blog posts 2008-05-05
- << Previous
- page 1 of 1
- Next >>
Presented by American Express